Ignite Creation Date:
2024-05-05 @ 4:50 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00320346
Status:
COMPLETED
Last Update Posted:
2016-07-19
First Post:
2006-05-01
Brief Title:
Phase II Study of Pandemic Influenza Vaccine
Sponsor:
Seqirus
Organization:
Seqirus
Study Overview
Official Title:
A Double-Blind Randomised Multi-Centre Study to Evaluate the Safety Tolerability Immunogenicity and Lot to Lot Consistency of Two Formulations of CSL Limiteds Inactivated Prototype Pandemic Influenza Vaccine in a Healthy Adult Population 18 Years to 64 Years of Age
Status:
COMPLETED
Status Verified Date:
2008-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The World Health Organisation has warned that an influenza pandemic is inevitable The avian influenza H5N1 virus strain is the leading candidate to cause the next influenza pandemic This study will test the safety and immunogenicity of a H5N1 Pandemic Influenza Vaccine in healthy adults The Study will also assess Lot to Lot consistency of the Pandemic Influenza Vaccine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None